DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
issued a press release announcing its financial results for its
first quarter ended March 31, 2017. A copy of that press release
and the attached financial schedules are attached as Exhibit 99.1
to this report and incorporated herein by reference.
furnished to Item 2.02 and shall not be deemed to be filed for
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section, nor shall it be deemed to be
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act.
|
Exhibit Number
|
Description
|
|
|
99.1
|
Press release dated May 15, 2017, announcing financial
results for the first quarter ended March 31, 2017. |
About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases. DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Recent Trading Information
DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) closed its last trading session down -0.01 at 2.96 with 152 shares trading hands.
